Jan 9, 2025 - News
Mapped: Weight-loss drugs
Add Axios as your preferred source to
see more of our stories on Google.
Even as the popularity and availability of weight-loss drugs — GLP1s like Ozempic, Wegovy and Mounjaro — increased across the U.S., fewer Arkansas prescriptions were picked up last year.
Why it matters: The data offers a snapshot of where these drugs, seen as game-changers in the fight against obesity, are most in demand in the United States.
Zoom in: The number of GLP-1 prescriptions dispensed dropped 1.4% between 2023 and 2024, according to insurance claims data from the health analytics company PurpleLab.
- More than 535,706 GLP-1 prescriptions were filled statewide in 2024, per data the company shared with Axios.